Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.

Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.

Clinical failure is measured by:

1. Systemic antifungal therapy for > 14 consecutive days for suspected fungal infection up to week 14.

2. Breakthrough proven or probable fungal infection during the prophylaxis phase.*

3. Toxicity leading to permanent discontinuation of prophylaxis

4. Adverse event requiring discontinuation.

   • The prophylaxis phase was defined as the period from the first dose of isavuconazole through 7 days after discontinuation of isavuconazole.

Clinical failure is measured by:

1. Systemic antifungal therapy for > 14 consecutive days for suspected fungal infection up to week 14.

2. Breakthrough proven or probable fungal infection during the prophylaxis phase.*

3. Toxicity leading to permanent discontinuation of prophylaxis

4. Adverse event requiring discontinuation.

   • The prophylaxis phase was defined as the period from the first dose of isavuconazole through 7 days after discontinuation of isavuconazole.

Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.

Isavuconazole: Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.

Clinical failure is measured by:

1. Systemic antifungal therapy for > 14 consecutive days for suspected fungal infection up to week 14.

2. Breakthrough proven or probable fungal infection during the prophylaxis phase.*

3. Toxicity leading to permanent discontinuation of prophylaxis

4. Adverse event requiring discontinuation.

   • The prophylaxis phase was defined as the period from the first dose of isavuconazole through 7 days after discontinuation of isavuconazole.

Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.

Isavuconazole: Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.